The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease
- PMID: 27940475
- PMCID: PMC5324712
- DOI: 10.1182/blood-2016-09-691394
The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease
Erratum in
-
Staffas A, Burgos da Silva M, van den Brink MRM. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood. 2017;129(8):927-933.Blood. 2017 Apr 13;129(15):2204. doi: 10.1182/blood-2017-03-771543. Blood. 2017. PMID: 28408426 Free PMC article. No abstract available.
Abstract
Hematopoietic cell transplantation (HCT) is a critical treatment of patients with high-risk hematopoietic malignancies, hematological deficiencies, and other immune diseases. In allogeneic HCT (allo-HCT), donor-derived T cells recognize host tissues as foreign, causing graft-versus-host disease (GVHD) which is a main contributor to morbidity and mortality. The intestine is one of the organs most severely affected by GVHD and research has recently highlighted the importance of bacteria, particularly the gut microbiota, in HCT outcome and in GVHD development. Loss of intestinal bacterial diversity is common during the course of HCT and is associated with GVHD development and treatment with broad-spectrum antibiotics. Loss of intestinal diversity and outgrowth of opportunistic pathogens belonging to the phylum Proteobacteria and Enterococcus genus have also been linked to increased treatment-related mortality including GVHD, infections, and organ failure after allo-HCT. Experimental studies in allo-HCT animal models have shown some promising results for prebiotic and probiotic strategies as prophylaxis or treatment of GVHD. Continuous research will be important to define the relation of cause and effect for these associations between microbiota features and HCT outcomes. Importantly, studies focused on geographic and cultural differences in intestinal microbiota are necessary to define applicability of new strategies targeting the intestinal microbiota.
© 2017 by The American Society of Hematology.
Figures

Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.Dig Dis Sci. 2019 Mar;64(3):669-677. doi: 10.1007/s10620-018-5369-9. Epub 2018 Dec 7. Dig Dis Sci. 2019. PMID: 30523482 Review.
-
The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.Cancer. 2022 Apr 1;128(7):1402-1410. doi: 10.1002/cncr.34091. Epub 2022 Jan 25. Cancer. 2022. PMID: 35077579
-
Intestinal microbiota-related effects on graft-versus-host disease.Int J Hematol. 2015 May;101(5):428-37. doi: 10.1007/s12185-015-1781-5. Epub 2015 Mar 27. Int J Hematol. 2015. PMID: 25812838 Free PMC article. Review.
-
Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. doi: 10.1016/j.bbmt.2020.04.001. Epub 2020 Apr 10. Biol Blood Marrow Transplant. 2020. PMID: 32283185 Free PMC article.
Cited by
-
Probiotics in Cancer.Front Oncol. 2021 Mar 12;11:638148. doi: 10.3389/fonc.2021.638148. eCollection 2021. Front Oncol. 2021. PMID: 33791223 Free PMC article. Review.
-
Inflammatory Modulation Effects of Probiotics: A Safe and Promising Modulator for Cancer Prevention.Curr Microbiol. 2024 Sep 23;81(11):372. doi: 10.1007/s00284-024-03901-8. Curr Microbiol. 2024. PMID: 39312034 Review.
-
Microbiota-Dependent Effects of IL-22.Cells. 2020 Sep 29;9(10):2205. doi: 10.3390/cells9102205. Cells. 2020. PMID: 33003458 Free PMC article. Review.
-
Relationship between clostridium difficile infection and gastrointestinal graft versus host disease in recipients of allogeneic stem cell transplantation.Bone Marrow Transplant. 2019 Jan;54(1):164-167. doi: 10.1038/s41409-018-0270-x. Epub 2018 Jul 23. Bone Marrow Transplant. 2019. PMID: 30038352 Free PMC article. Clinical Trial. No abstract available.
-
Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation.Turk J Gastroenterol. 2019 Feb;30(2):122-131. doi: 10.5152/tjg.2018.18156. Turk J Gastroenterol. 2019. PMID: 30459131 Free PMC article. Review.
References
-
- Pasquini MC, Zhu X. Current uses and outcomes of hematopoietic stem cell transplantation: CIBMTR summary slides. Available at: http://www.cibmtr.org. Accessed 18 September 2016.
-
- Ott SJ, Kühbacher T, Musfeldt M, et al. Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol. 2008;43(7):831-841. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources